Company: STAA
Filing Date: 2025-12-11
Form Type: DFAN14A
Source: 0001213900-25-120777
Chunk: 12

Company: STAAR SURGICAL CO
Filing Date: 2025-12-11
Form: DFAN14A
Chunk 12
---
during the go - shop period]… [The go - shop] produced the best buyer for STAAR” Interest from a Credible Counterparty During the Go - Shop 1. Source: STAAR Investor Presentation, September 26, 2025. 2. Source: STAAR Press Release, November 7, 2025. 3. Source: STAAR Press Release, December 8, 2025.

CONFIDENTIAL © All rights reserved. Two Seas Capital LP SUPPLEMENTAL INVESTOR PRESENTATION STILL THE WRONG PRICE 03

Broadwood Partners, L.P. We Believe the Price Remains Inadequate and Not a Reflection of Fair Value 17 ▪ Sector valuation multiples have increased over the last three months, supporting a higher price for STAAR ▪ The Proposed Merger values STAAR below the median of a group of comparable medical technology companies The Proposed Merger Values STAAR Below Comparable MedTech Companies… ▪ The deal’s multiple is substantially below STAAR’s historical multiples …The Company’s Historical Valuation Multiple… ▪ An appropriate discount rate and management’s original projections yield a significantly higher valuation range than the revi sed price …Reasonable Estimates of Intrinsic Value… ▪ Historically, STAAR has traded at prices well above $30 per share …STAAR’s Historical Stock Price… ▪ The Proposed Merger price is well below historical analyst price targets for STAAR which, up until the Company released Q4 20 24 earnings in February 2025, had been well above $40 for several years …And Historical Analyst Price Targets ▪ STAAR’s expected growth and margins also support a significantly higher valuation multiple and a price of approximately $40 p er share or more STAAR’s Trading and Expected Growth Should Have Inspired a Higher Premium ▪ When Alcon first emerged as a suitor in April 2024 with an offer to acquire the Company for $58 per share in cash, the Board con cluded that the Company’s standalone business plan represented the best path forward and determined not to engage further with Alcon ▪ Now, the Board has concluded that STAAR is only worth $30.75 per share, even though the Company’s prospects have not changed mea ningfully The Price Is Well Below Alcon’s Prior Offers 1 2 4 5 6 3 7

Broadwood Partners, L.P. MedTech Multiples Have Expanded Significantly Over the Last Three Months 18 Since we began soliciting votes